Consolidated Balance Sheets - USD ($) $ in Millions		Sep. 30, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents		$ 5,344	$ 4,619
Investments		1,324	937
Accounts receivable, net		13,488	10,716
Inventories		2,657	2,661
Other current assets		1,722	1,400
Assets of business held for sale		10,022	9,512
Total current assets		34,557	29,845
Long-term investments		21,952	21,542
Reinsurance recoverables		4,898	5,100
Deferred policy acquisition costs		3,161	2,958
Property and equipment		4,203	4,417
Goodwill		44,685	44,602
Other intangible assets		35,492	36,562
Other assets		2,480	2,283
Separate account assets		8,616	8,465
TOTAL ASSETS		160,044	155,774
Liabilities
Current insurance and contractholder liabilities		5,223	4,921
Pharmacy and service costs payable		12,539	10,454
Accounts payable		5,327	5,090
Accrued expenses and other liabilities		7,153	7,347
Short-term debt		6,449	5,514
Liabilities of business held for sale		7,195	6,812
Total current liabilities		43,886	40,138
Non-current insurance and contractholder liabilities		16,213	16,052
Deferred tax liabilities, net		9,142	9,387
Other non-current liabilities		4,552	4,460
Long-term debt		29,537	31,893
Separate account liabilities		8,616	8,465
TOTAL LIABILITIES		111,946	110,395
Contingencies — Note 18
Redeemable noncontrolling interests		59	35
Shareholders’ equity
Common stock	[1]	4	4
Additional paid-in capital		28,777	28,306
Accumulated other comprehensive loss		(541)	(941)
Retained earnings		24,440	20,162
Less: treasury stock, at cost		(4,648)	(2,193)
TOTAL SHAREHOLDERS’ EQUITY		48,032	45,338
Other noncontrolling interests		7	6
Total equity		48,039	45,344
Total liabilities and equity		$ 160,044	$ 155,774

[1] Par value per share, $0.01; shares issued, 389 million as of September 30, 2020 and 386 million as of December 31, 2019; authorized shares, 600 million.